Chief Medical Officer
Victoria Manax M.D., is a medical oncologist with over 20 years of experience in solid tumor cancer states. She specializes in global drug development, medical affairs, and patient advocacy. Dr. Manax has been involved in the development, approval, and launch of multiple billion-dollar drugs including the standard of care for pancreatic cancer, Abraxane. Most well-known for innovative clinical trial designs, Dr. Manax has managed many $100M global clinical trial programs and is a well-known panelist amongst regulatory agencies around the world. She currently holds several clinical advisory positions, patents, and chair positions for multiple data, safety, and monitoring boards. Dr. Manax is on the board for TrovaNOW, Data Safety Monitoring Chair (DSMC) of REMAP-CAP for COVID-19, and DSMC co-chair for ATTACC (Antithrombotic Therapy to Ameliorate Complications of COVID-19). She most recently served as the Chief Medical Officer of the Pancreatic Cancer Action Network and was the GI Disease Lead at Celgene.